Cristina Zalfa

Cristina Zalfa

Auto-generated profile, based on publicly available information

Cristina Zalfa

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DLDuy Tri Le
Duy Tri Le
BBBryan M. Burt
Bryan M. Burt
GIGeorge Van Buren, II
George Van Buren, II
SAShawn Alaron Abeynaike
Shawn Alaron Abeynaike
CZCristina Zalfa
Cristina Zalfa
SPSilke Paust
Silke Paust
Existing patient-derived-xenograft (PDX) mouse models of solid tumors lack a fully tumor-donor matched “syngeneic” and functional immune system. We developed such a model by engrafting lymphopenic recipient mice with a fresh undisrupted piece of solid tumor, whereby tumor-infiltrating lymphocytes (TIL) expanded in the recipient mice for several weeks. Tumors engrafted in about seventy to eighty percent of s yngeneic- i mmune- s ystem-PDX (SIS-PDX) mice, which harbored tumor-exhausted immune-effector and functional immune-regulatory cells persisting for at least six-months post-engraftment. Interleukin-15 (IL-15)-stimulation in addition to immune checkpoint inhibition (ICI), prevented resistance, resulting in complete or partial response to combined treatment. Further, the depletion of Cytotoxic T lymphocytes (CTLs) and/or Natural Killer (NK) cells from combined immunotherapy in SIS-PDX mice revealed that both cell types are required for the maximal response to tumor. Our novel SIS-PDX model provides a valuable resource for powerful mechanistic and therapeutic studies designed to eradicate solid tumors.